Become A Wiser, More Profitable Investor

🗞️   In Brief This Week: Thermo Fisher Scientific, GeneDx, IDT, Psomagen, Danaher, More

business

NEW YORK – Thermo Fisher Scientific has carried out a restructuring and headcount reduction during Q1 of 2025, according to the company's quarterly filing with the US Securities and Exchange Commission last week. Thermo Fisher said the layoffs and facility consolidations, which affected approximately 1 percent of its workforce, are part of its efforts to streamline operations. The company said it has identified restructuring actions, primarily in the laboratory products and biopharma services business segments, that are expected to result in additional charges of approximately $120 million in restructuring costs, primarily in 2025.

Genome Web     May 09, 2025